Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Company Announcements

Investors

IR Nav

  • Overview
  • News, Events & Presentations
    • Press Releases
    • Company Announcements
    • Events
    • Corporate Presentations
  • Stock Information
    • Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • SEDAR Filings
    • Financial Reports
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Investor Resources
    • Contact IR
    • FAQs

Stock

Prices shown in CAD

Mar 25, 2023 12:30 AM EDT

btn Stock

Learn More

IR Tools

  • Email Alerts
  • Contact IR
  • RSS Feeds

Company Announcements

Latest

Jan 04, 2023
Open Letter to Shareholders from CEO Paul Levesque
news
Company Announcements
Jan 04, 2023
Open Letter to Shareholders from CEO Paul Levesque
Aug 02, 2022
Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference
Oct 12, 2021
Q3 Earnings Call – Participant Q&A via Webcast
Jun 15, 2021
Welcome to Theratechnologies’ new website!
Apr 11, 2021
Posters et Abstracts Presented at AACR 2021
Jun 10, 2020
Virtual panels on NASH organized by the Global Liver Institute
Jun 08, 2020
Theratechnologies a proud sponsor of NY AIDS WALK 2020
Apr 24, 2020
Message from the President and CEO
Apr 13, 2020
Reminder about our First Quarter Financial Results Conference Call
Apr 13, 2020
Data on NASH from Dr. Steven Grinspoon
  • Current page 1
  • Page 2
  • Page 3
  • Next page ›
  • Last page »
Displaying 1 - 10 of 26

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
2 Hume Street, 4th floor
Dublin 2
Ireland D02 DV24
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Elif McDonald
Senior Director, Investor Relations
Phone: +1-438-315-8563
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Corporate Responsibility
  • Careers
  • Contact Us
©2023 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies